Efficacy and safety of OCTANINE F in children with haemophilia B

Haemophilia ◽  
2008 ◽  
Vol 14 (3) ◽  
pp. 531-538 ◽  
Author(s):  
A. KLUKOWSKA ◽  
P. LAGUNA ◽  
P. SVIRIN ◽  
E. SHILLER ◽  
V. VDOVIN
Keyword(s):  
Efficacy And Safety ◽  
Haemophilia B

scholarly journals Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B

Haemophilia ◽  
2021 ◽  
Author(s):  
Johnny Mahlangu ◽  
Howard Levy ◽  
Martin Lee ◽  
Frank Del Greco
Keyword(s):  
Efficacy And Safety ◽  
Haemophilia B

An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B

Haemophilia ◽  
2009 ◽  
Vol 16 (2) ◽  
pp. 240-246 ◽  
Author(s):  
T. LISSITCHKOV ◽  
M. MATYSIAK ◽  
K. ZAWILSKA ◽  
L. GERCHEVA ◽  
A. ANTONOV ◽  
...  
Keyword(s):  
Clinical Study ◽  
High Purity ◽  
Factor Ix ◽  
Severe Haemophilia ◽  
Efficacy And Safety ◽  
Haemophilia B

Idelvion® as a modern treatment option for haemophilia B (Sponsor: CSL Behring GmbH)

2020 ◽  
Vol 12 (01) ◽  
pp. 1-20
Keyword(s):  
Fusion Protein ◽  
Safety Profile ◽  
Factor Ix ◽  
Efficacy And Safety ◽  
Haemophilia B ◽  
Previous Therapy ◽  
Injection Frequency ◽  
Recombinant Factor Ix ◽  
Modern Treatment ◽  
Long Acting

ZusammenfassungIdelvion® (albutrepenonacog alfa, rIX-FP) is a long-acting recombinant factor IX (FIX) albumin fusion protein indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B. It allows prophylaxis intervals of up to 14 days.* Compared with previous therapy, this fusion protein allows for a significant reduction in injection frequency while maintaining a favourable efficacy and safety profile.

A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high-purity factor IX concentrate, in patients with severe haemophilia B

Haemophilia ◽  
2011 ◽  
Vol 17 (4) ◽  
pp. 590-596 ◽  
Author(s):  
T. LISSITCHKOV ◽  
M. MATYSIAK ◽  
K. ZAVILSKA ◽  
P. ŁAGUNA ◽  
L. GERCHEVA ◽  
...  
Keyword(s):  
Clinical Study ◽  
High Purity ◽  
Factor Ix ◽  
Severe Haemophilia ◽  
Efficacy And Safety ◽  
Haemophilia B

scholarly journals Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

Haemophilia ◽  
2016 ◽  
Vol 22 (4) ◽  
Author(s):  
C. Négrier ◽  
F. Abdul Karim ◽  
L. M. Lepatan ◽  
A. Lienhart ◽  
M. F. López‐Fernández ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Ix ◽  
Recombinant Fusion Protein ◽  
Efficacy And Safety ◽  
Haemophilia B ◽  
Long Acting

Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures

Haemophilia ◽  
1997 ◽  
Vol 3 (4) ◽  
pp. 247-253 ◽  
Author(s):  
A. D. Shapiro ◽  
G. C. White II ◽  
H. C. Kim ◽  
J. M. Lusher ◽  
G. E. Bergman
Keyword(s):  
Monoclonal Antibody ◽  
Surgical Procedures ◽  
Factor Ix ◽  
Efficacy And Safety ◽  
Haemophilia B

Reformulated BeneFix�: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

Haemophilia ◽  
2007 ◽  
Vol 13 (3) ◽  
pp. 233-243 ◽  
Author(s):  
T. LAMBERT ◽  
M. RECHT ◽  
L. A. VALENTINO ◽  
J. S. POWELL ◽  
C. UDATA ◽  
...  
Keyword(s):  
Severe Haemophilia ◽  
Efficacy And Safety ◽  
Haemophilia B ◽  
Previously Treated Patients ◽  
Previously Treated

A new strategy for prenatal diagnosis in a sporadic haemophilia B family

Haemophilia ◽  
2001 ◽  
Vol 7 (4) ◽  
pp. 416-418 ◽  
Author(s):  
M. Acquila ◽  
F. Bottini ◽  
A. Valetto ◽  
D. Caprino ◽  
P. G. Mori ◽  
...  
Keyword(s):  
Prenatal Diagnosis ◽  
Haemophilia B ◽  
New Strategy
Sign in / Sign up

Export Citation Format

Share Document